Avadel Pharmaceuticals (AVDL) Enterprise Value: 2009-2022
Historic Enterprise Value for Avadel Pharmaceuticals (AVDL) over the last 14 years, with Sep 2022 value amounting to $193.1 million.
- Avadel Pharmaceuticals' Enterprise Value fell 50.89% to $193.1 million in Q3 2022 from the same period last year, while for Sep 2022 it was -$191.7 million, marking a year-over-year increase of 18.78%. This contributed to the annual value of $1.0 billion for FY2024, which is N/A change from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Enterprise Value of $193.1 million as of Q3 2022, which was up 383.54% from $39.9 million recorded in Q2 2022.
- Over the past 5 years, Avadel Pharmaceuticals' Enterprise Value peaked at $393.2 million during Q3 2021, and registered a low of -$26.1 million during Q1 2019.
- Moreover, its 3-year median value for Enterprise Value was $231.1 million (2020), whereas its average is $223.0 million.
- Within the past 5 years, the most significant YoY rise in Avadel Pharmaceuticals' Enterprise Value was 5,041.04% (2019), while the steepest drop was 133.20% (2019).
- Quarterly analysis of 5 years shows Avadel Pharmaceuticals' Enterprise Value stood at -$4.4 million in 2018, then soared by 5,041.04% to $218.6 million in 2019, then fell by 23.21% to $167.9 million in 2020, then surged by 88.51% to $316.4 million in 2021, then tumbled by 50.89% to $193.1 million in 2022.
- Its Enterprise Value was $193.1 million in Q3 2022, compared to $39.9 million in Q2 2022 and $279.7 million in Q1 2022.